TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function.
Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.
Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.
We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.
Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.
Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.
We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.
Location: France, Ile-de-France, Paris
Employees: 51-200
Total raised: $164.68M
Founded date: 2013
Investors 8
Funding Rounds 4
| Date | Series | Amount | Investors |
| 23.05.2023 | Series D | $54.11M | - |
| 01.09.2021 | Series C | $59.17M | - |
| 01.10.2020 | - | $8.2M | - |
| 26.11.2019 | Series B | $43.2M | - |
Mentions in press and media 21
| Date | Title | Description |
| 17.12.2025 | 3D Systems Secures FDA Clearance to Broaden Adolescent Use of VSP Orthopedics Platform | US-based 3D printer manufacturer 3D Systems has received U.S. Food and Drug Administration 510(k) clearance broadening the approved use of its VSP Orthopedics virtual surgical planning and patient-specific instrumentation platform. The clea... |
| 01.09.2025 | Tissium receives FDA authorization for suture-free nerve repair system | Tissium, a Paris-based medical technology company founded on MIT research, has secured De Novo marketing authorization from the U.S. Food and Drug Administration for its non-traumatic peripheral nerve repair platform. The clearance enables ... |
| 30.06.2025 | 3D Systems and TISSIUM Receive FDA Approval for First-of-its-Kind Peripheral Nerve Repair Device | U.S.-based 3D printer manufacturer 3D Systems, in partnership with French MedTech firm TISSIUM, has secured FDA approval for a bioabsorbable, 3D printed device designed to treat peripheral nerve damage. This approval validates the polymer’s... |
| 27.06.2025 | FDA clears path for Paris startup TISSIUM's tissue reconstruction without sutures, redefining surgical standards | Nerve injuries affect hundreds of thousands of patients each year. Typically, they’re repaired using microsurgical stitches. However, the process is technically complex, with a risk of additional trauma to surrounding tissues and long perio... |
| 23.05.2023 | French medtech startup TISSIUM bags €50M to transform tissue reconstruction: Here’s how | Paris-based TISSIUM, a medtech company developing biomorphic programmable polymers for tissue reconstruction, announced on Tuesday that it has closed €50M in a Series D round of funding. The financing comes from new and existing internation... |
| 23.05.2023 | Tissium Raises $50M in Series D Funding | Tissium, a Paris, France and Boston, MA-based medtech company developing biomorphic programmable polymers for tissue reconstruction, raised $50M in Series D funding. The round saw participation from Fonds Stratégique des Transitions, manage... |
| 23.05.2023 | Paris-based TISSIUM raises €50 million in Series D round to launch its first tissue reconstruction products | - |
| 01.09.2021 | Medtech startup Tissium pockets €50M Series C | Paris-based Tissium has raised €50 million in a round led by Cathay Capital and Sofinnova Partners. The startup develops biodegradable sealants and adhesives for tissue repair and reconstruction. The funds bring the company closer to the co... |
| 31.08.2021 | Tissium Raises €50M in Series C Financing | Tissium, a Paris, France- and Boston, MA-based medtech company developing biomorphic programmable polymers for tissue reconstruction, raised €50M in Series C financing. The round was led by Cathay Health, affiliated to global investment fir... |
| 31.08.2021 | Databricks CEO on why Morgan Stanley is leading its new round of funding | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Why the Electricity 4.0 moment is here From Schneider Electric There’s plenty of tal... |
Show more